Our aim is to ensure the healthcare professionals we work with in the UK have the tools needed to continue patient care, even in the uncertain times ahead. We see the UK distribution centre as essential to how we operate here in the UK as a way of minimising the impact that wider national and global situations may have on our product supply.
In addition to the immediate benefits with regards to efficient supply chain and reduced carbon footprint, the new UK distribution centre provides new and exciting opportunities for us to explore additional logistical services to benefit customers in the future.
Adding oxygen therapy to our leading range of healing solutions for chronic wounds is a fundamental milestone for Mölnlycke in advancing wound care in this progressive and rapidly developing region
This exciting new technology will help reduce the incidence of serious infection and minimise the unnecessary use of antibiotics.
This is fully in line with where we want to be as a company, and M&J’s strong R&D capabilities combined with Mölnlycke’s end-product knowledge will help us further improve our competitive position within the advanced wound care industry.
We believe that the Mepilex Border Flex dressing may change the way wound care experts practice
'Today, chronic wounds, such as foot ulcers, have a higher mortality rate than both breast cancer and prostate cancer and the real burden of ulcers is not yet fully known or understood. '
Mӧlnlycke’s dedication to pressure injury prevention is an example of our shared commitment with the WOCN Society
These market practices that allow extrapolation of evidence from one specific product to another similar type of product, even though the latter is not equivalent in material construction and design to the former, can put patients at risk.
Compared with the rigorous and thorough processes in place within the pharmaceutical industry for extrapolation of clinical evidence of efficacy from one product to another, parts of the medical devices industry is operating in a grey zone.
Healthcare systems are under pressure to deliver better care to more people with a better value. Right now, healthcare is focused on outcomes. By focusing on prevention issues, you are able to help reduce some costs to the healthcare systems. Our solutions are designed to help reduce the risk of infection, hospital readmissions, and hospital acquired conditions. These are things that can lead to much higher costs, much higher patient suffering, and longer length of stay.
Hibiclens isn’t just for the hospital – it also works in the home. That is why we continue to expand our retail availability to make it easier for consumers to buy Hibiclens. Because it bonds to your skin and has 24-hour protection, you’re able to resist the multitude of germs you come across in your daily lives.
Mölnlycke is doing things right. Healthcare should always come first.
Our solutions are true to Mölnlycke’s purpose of advance performance in healthcare across the world. When looking at the patient and caregiver experience, we aspire to equip both with solutions to achieve the best outcomes. This is why we care about prevention of Surgical Site Infections. Simply put, we know they are a significant issue impacting patient care and increasing health care costs and we want to be the best partner in making a positive difference in this space.
Continued caregiver and patient understanding is important to us and central to what we call having ‘Customer at Heart’. Combined with our gained expertise and advanced technologies, we’ve developed a portfolio of SSI bundle solutions for perioperative care. Mölnlycke truly believes that together we can make a difference. Everyone involved - the patient, health care provider, the care facility and our healthcare system overall- benefits when we are able to work together to reduce infection rates.
Tissue Analytics is incredibly excited to work with Mölnlycke on this important initiative. We share the same passion to help patients.
We are very excited to be part of AstraZeneca’s BioVentureHub, as it offers a unique opportunity for us to collaborate with AstraZeneca’s world-class scientists and benefit from their state-of-the-art facilities and infrastructure while developing new advanced wound care and surgical solutions for our customers.
It’s fantastic that a well-established, global, medical solutions company like Mölnlycke wants to be part of our innovation experiment.
Our strong focus on product innovation and clinical evidence has continuously changed the way wounds are treated and prevented.
This reconfirms market confidence in Mölnlycke and our sound, long-term corporate strategy
Skin protectants are strategically important to our Prevention solution offer and the partnership with Rochal enables us to provide our customers with a complete solution within the pressure ulcer prevention area
It is our hope that the WUWHS consensus document will help clinicians and health care budget holders understand the role of dressings in PU prevention, as well as which dressings may protect against PU development and which patients may benefit.
The results of this research will contribute to developing a better understanding of the hidden costs of wound care and also, ultimately, to better patient care.
We finally have a product that really works; this is fantastic news for cancer patients.
The BARRIER EasyWarm active self-warming blanket is a welcome addition to the tools available to healthcare professionals
being granted FDA clearance gives us access to another important market, where we will launch during 2014